Europe and Japan have yet to start ramp and US is still in early stages.
i.e. only half of US doctors who are treating HCV patients have yet to perscribe.
Even with compatition coming their run rate will level off far higher than Q 1's results and maintain that for years to come as they secure their share of the market,. i.e they don't have to dominate it.